NASDAQ: SNSE - Sensei Biotherapeutics, Inc.

Rentabilidad a seis meses: -15%
Rendimiento de dividendos: 0.00%
Sector: Healthcare

Calendario de promoción Sensei Biotherapeutics, Inc.


Acerca de la empresa Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors.

más detalles
It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

IPO date 2021-02-04
ISIN US81728A1088
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.senseibio.com
Цена ао 0.436
Cambio de precio por día: +17.99% (0.4308)
Cambio de precio por semana.: +3.73% (0.49)
Cambio de precio por mes: +12.23% (0.4529)
Cambio de precio en 3 meses.: +2.07% (0.498)
Cambio de precio en seis meses: -15% (0.598)
Cambio de precio por año: -51.59% (1.05)
Cambio de precio en 3 años.: -80.07% (2.55)
Cambio de precio desde principios de año.: +3.71% (0.4901)

Subestimación

Nombre Significado Calificación
P/S 0 0
P/BV 0.2886 10
P/E 0 0
EV/EBITDA -0.3268 0
Total: 3.75

Eficiencia

Nombre Significado Calificación
ROA, % -45.85 0
ROE, % -52.55 0
Total: 0

Dividendos

Nombre Significado Calificación
Div yield, % 0 0
DSI 0 0
Total: 0

Deber

Nombre Significado Calificación
Debt/EBITDA -0.1701 10
Total: 10

Impulso de crecimiento

Nombre Significado Calificación
Rentabilidad Revenue, % 0 0
Rentabilidad Ebitda, % 169.24 10
Rentabilidad EPS, % -20.78 0
Total: 5.6



Supervisor Título profesional Pago año de nacimiento
Mr. John K. Celebi M.B.A. President, CEO & Director 882.28k 1972 (53 año)
Dr. Edward Van der Horst Ph.D. Chief Scientific Officer 630.81k 1974 (51 año)
Ms. Lora Pike Vice President of Investor Relations & Communications N/A
Mr. Christopher W. Gerry J.D. Senior VP, General Counsel & Secretary N/A
Ms. Stephanie Krebs M.B.A., M.S. Chief Business Officer N/A 1978 (47 años)
Dr. Aaron Weitzman FACP, M.D., Ph.D. Chief Medical Officer N/A
Mr. Josiah Craver Senior VP of Finance, Principal Financial Officer & Principal Accounting Officer

DIRECCIÓN: United States, Rockville. MD, 1405 Research Boulevard - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.senseibio.com